Migraine pathophysiology

Headache

Volumn 45, Issue SUPPL. 1, 2005, Pages

  Goadsby, Peter J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Genetics; Migraine; Neuropeptides; Nociceptor; Pathophysiology; Trigeminal pain

Indexed keywords

ACETYLSALICYLIC ACID; CALCITONIN GENE RELATED PEPTIDE; ERGOT ALKALOID; INDOMETACIN; SUBSTANCE P; SUMATRIPTAN; VASOACTIVE INTESTINAL POLYPEPTIDE;

CENTRAL NERVOUS SYSTEM; CHROMOSOME 19; EXTRAVASATION; FAMILIAL HEMIPLEGIC MIGRAINE; GENETIC ASSOCIATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; THALAMUS; TRIGEMINAL NERVE; TRIGEMINUS GANGLION;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; MIGRAINE DISORDERS; PERIPHERAL NERVOUS SYSTEM;

EID: 17244383233     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.4501003.x     Document Type: Review

References (128)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine- current understanding and treatment. N Engl J Med. 2002;346:257-270.
2. Menken M, Munsat TL, Toole JF. The global burden of disease study - implications for neurology. Arch Neurol. 2000;57:418-420.
3. Lance JW, Goadsby PJ. Mechanism and Management of Headache. New York: Elsevier; 2005.
4. Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice. London: Martin Dunitz; 2002.
5. Willis T. Opera Omnia Amstelaedami: Henricum Wetstenium, 1682.
6. Russell MB. Genetic epidemiology of migraine and cluster headache. Cephalalgia. 1997;17:683-701.
7. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB. Evidence of a genetic factor in migraine with aura: a population based Danish twin study. Ann Neurol. 1999;45:242-246.
8. Mochi M, Sangiorgi S, Cortelli P, et al. Testing models for genetic determination in migraine. Cephalalgia. 1993;13:389-394.
9. Lalouel JM, Morton NE. Complex segregation analysis with pointers. Human Hereditary. 1981;31:312-321.
10. Russell MB, Iselius L, Olesen J. Investigation of the inheritance of migraine by complex segregation analysis. Hum Genet. 1995;96:726-730.
11. Joutel A, Ducros A, Vahedi K, et al. Genetic heterogeneity of familial hemiplegic migraine. Am J Hum Genet. 1994;55:1166-1172.
12. Ophoff RA, Eijk Rv, Sandkuijl LA, et al. Genetic heterogeneity of familial hemiplegic migraine. Genomics. 1994;22:21-26.
13. Ducros A, Denier C, Joutel A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001;345:17-24.
14. Joutel A, Bousser MG, Biousse V, et al. A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet. 1993; 5:40-45.
15. Haan J, Terwindt GM, Bos PL, et al. Familial hemiplegic migraine in the Netherlands. Clin Neurol Neurosurg. 1994;96:244-249.
16. Teh BT, Silburn P, Lindblad K, et al. Familial cerebellar periodic ataxia without myokymia maps to a 19-cM region on 19p13. Am J Hum Genet. 1995;56:1443-1449.
17. Terwindt GM, Ophoff RA, Haan J, Ferrari MD, The Dutch Migraine Genetics Research Group. Familial hemiplegic migraine: a clinical comparison of families linked and unlinked to chromosome 19. Cephalalgia. 1996;16:153-155.
18. 2+ channel gene CACNL1A4. Cell. 1996;87:543-552.
19. Ertel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron. 2000;25:533-535.
20. Marconi R, De Fusco M, Aridon P, et al. Familial hemiplegic migraine type 2 is linked to 0.9Mb region on chromosome 1q23. Ann Neurol. 2003;53:376-381.
21. + pump α2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003;33:192-196.
22. +-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol. 2003;54:360-366.
23. Jurkat-Rott K, Freilinger T, Dreier JP, et al. Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants. Neurology. 2004;62:1857-1861.
24. Swoboda KJ, Kanavakis E, Xaidara A, et al. Alternating hemiplegia of childhood or familial hemiplegic migraine?: a novel ATP1A2 mutation. Ann Neurol. 2004;55:884-887.
25. Goadsby PJ, Ferrari MD. Migraine: a multifactorial, episodic neurovascular channelopathy? In: Rose MR, Griggs RC, eds. Channelopaties of the Nervous System. Oxford: Butterworth Heinemann; 2001:274-292.
26. van den Maagdenberg AMJM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knock-in migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004;41:701-710.
27. Goadsby PJ. Migraine aura: a knock-in mouse with a knock-out message. Neuron. 2004;41:679-680.
28. Liu-Chen L-Y, Gillespie SA, Norregaard TV, Moskowitz MA. Co-localization of retrogradely transported wheat germ agglutinin and the putative neurotransmitter substance P within trigeminal ganglion cells projecting to cat middle cerebral. J Comp Neurol. 1984;225:187-192.
29. Arbab MA-R, Wiklund L, Svendgaard NA. Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat. Neuroscience. 1986;19:695-708.
30. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62:131-136.
31. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigemino-vascular system. Ann Neurol. 1988;23:193-196.
32. Feindel W, Penfield W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology. 1960;10:555-563.
33. Penfield W, McNaughton FL. Dural headache and the innervation of the dura mater. Arch Neurol Psychiatry. 1940;44:43-75.
34. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin. 1990;8:801-815.
35. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci. 1987;7:4129-4136.
36. Moskowitz MA, Cutrer FM. SUMATRIPTAN: a receptor-targeted treatment for migraine. Ann Rev Med. 1993;44:145-154.
37. Cutrer FM, Limmroth V, Waeber C, Yu X, Moskowitz MA. New targets for antimigraine drug development. In: Goadsby PJ, Silberstein SD, eds. Headache. Philadelphia: Butterworth-Heinemann; 1997:59-72.
38. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience. 1991;44:97-112.
39. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience. 1992;48:187-203.
40. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998;79:964-982.
41. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996;384:560-563.
42. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002;8:136-142.
43. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of C-fos protein-like immunoreactivity within the trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci. 1993;13:1167-1177.
44. Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ. Possible mechanism of c-fos expression in trigeminal nucleus caudalis following spreading depression. Pain. 1997;72:407-415.
45. Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ. Comment on Ingvardsen et al., PAIN, 72 (1997) 407-415 - reply to Moskowitz et al. Pain. 1998;76:266-267.
46. Ebersberger A, Schaible H-G, Averbeck B, Richter F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol. 2001;41:7-13.
47. Goadsby PJ. Migraine, aura and cortical spreading depression: why are we still talking about it? Ann Neurol. 2001;49:4-6.
48. May A, Shepheard S, Wessing A, et al. Retinal plasma extravasation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. Brain. 1998;121:1231-1237.
49. Goldstein DJ, Wang O, Saper JR, et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia. 1997;17:785-790.
50. 1 receptor antagonist in the acute treatment of migraine. Cephalalgia. 1998;18:392.
51. Norman B, Panebianco D, Block GA. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia. 1998;18:407.
52. Diener H-C, The RPR100893 Study Group. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia. 2003;23:183-185.
53. Roon K, Diener HC, Ellis P, et al. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia. 1997;17:245.
54. Earl NL, McDonald SA, Lowy MT, 4991W93 Investigator Group. Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine. Cephalalgia. 1999;19:357.
55. May A, Gijsman HJ, Wallnoefer A, et al. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain. 1996;67:375-378.
56. Data J, Britch K, Westergaard N, et al. A double-blind study of ganaxolone in the acute treatment of migraine headaches with or without an aura in premenopausal females. Headache. 1998;38:380.
57. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack. Brain. 2000;123:1703-1709.
58. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614-624.
59. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26.
60. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitisation. Ann Neurol. 2004;55:27-36.
61. Lipton RB, Goadsby PJ. Acute management of migraine: clinical trials of triptans vs other agents. In: Olesen J, Ferrari MD, Humphrey PPA, eds. The Triptans: Novel Drugs in Migraine, 9th ed. Oxford: Oxford University Press; 2001:285-296.
62. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960;23:23-32.
63. Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol. 1998;5:329-341.
64. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19:115-127.
65. Matsuyama T, Shiosaka S, Matsumoto M, et al. Overall distribution of vasoactive intestinal polypeptide-containing nerves on the wall of the cerebral arteries: an immunohistochemical study using whole-mounts. Neuroscience. 1983;10:89-96.
66. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-187.
67. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15:384-390.
68. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain. 1994;117:427-434.
69. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995;60:119-123.
70. Goadsby PJ, Edvinsson L. Neuropeptide changes in a case of chronic paroxysmal hemicrania - evidence for trigemino-parasympathetic activation. Cephalalgia. 1996;16:448-450.
71. Iversen H. Human migraine models. Cephalalgia. 2001;21:781-785.
72. Afridi S, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004;110:675-680.
73. Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106:461-470.
74. Knight YE, Edvinsson L, Goadsby PJ. Blockade of CGRP release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. Neuropeptides. 1999;33:41-46.
75. 1B/1D receptor agonist activity. Neuropharmacology. 2001;40:520-525.
76. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129:420-423.
77. Olesen J, Diener H-C, Husstedt I-W, et al. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med. 2004;350:1104-1110.
78. Nozaki K, Boccalini P, Moskowitz MA. Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience. 1992;49:669-680.
79. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. Brain Res. 1993;629:95-102.
80. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat. 1997;190:367-375.
81. Hoskin KL, Zagami A, Goadsby PJ. Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat. 1999;194:579-588.
82. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain. 1991;114:1001-1011.
83. Goadsby PJ, Hoskin KL, Knight YE. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain. 1997;73:23-28.
84. Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain. 2002;125:1496-1509.
85. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurones to cervical input after stimulation of the dura mater. Brain. 2003;126:1801-1813.
86. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiology study. Brain. 1996;119:249-256.
87. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache. 1993;33:541-550.
88. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol. 1993;109:788-792.
89. Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain. 1999;82:15-22.
90. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res. 2002;953:181-188.
91. 1B/1D) receptors. Br J Pharmacol. 1997;122:918-922.
92. 1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia. 1998;18:659-664.
93. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997;328:37-40.
94. 1B/D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain. 1996;67:355-359.
95. 1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122:491-498.
96. Classey JD, Knight YE, Goadsby PJ. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. Brain Res. 2001;907:117-124.
97. Goadsby PJ, Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 2000;875:119-124.
98. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;142:1171-1181.
99. 1) receptors in the trigeminocervical complex. Ann Neurol. 2001;50:804-807.
100. 1F receptor immunoreactivity (IR) in the rat trigeminocervical complex (TCC) new therapeutic possibilities for the triptans. Cephalalgia. 2004;24:148.
101. Zagami AS, Goadsby PJ. Stimulation of the superior sagittal sinus increases metabolic activity in cat thalamus. In: Rose FC, ed. New Advances in Headache Research: 2. London: Smith-Gordon and Co Ltd; 1991:169-171.
102. Zagami AS, Lambert GA. Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat. Exp Brain Res. 1990;81:552-566.
103. Zagami AS, Lambert GA. Craniovascular application of capsaicin activates nociceptive thalamic neurons in the cat. Neurosci Lett. 1991;121:187-190.
104. Shields KG, Goadsby PJ. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128:86-97.
105. Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet. 2001;357:1016-1017.
106. Afridi S, Giffin NJ, Kaube H, et al. A PET study in spontaneous migraine. Arch Neurol. 2005: in press.
107. Afridi S, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005: in press.
108. Hoskin KL, Bulmer DCE, Lasalandra M, Jonkman A, Goadsby PJ. Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. J Anat. 2001;197:29-35.
109. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1:658-660.
110. Matharu MS, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127:220-230.
111. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987;27:416-420.
112. Veloso F, Kumar K, Toth C. Headache secondary to deep brain implantation. Headache. 1998;38:507-515.
113. Welch KM, Nagesh V, Aurora S, Gelman N. Periaqueductal grey matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41:629-637.
114. Goadsby PJ. Neurovascular headache and a midbrain vascular malformation- evidence for a role of the brainstem in chronic migraine. Cephalalgia. 2002;22:107-111.
115. Goadsby PJ, Lambert GA, Lance JW. Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. Brain Res. 1982;249:247-254.
116. Goadsby PJ, Lambert GA, Lance JW. The mechanism of cerebrovascular vasoconstriction in response to locus coeruleus stimulation. Brain Res. 1985;326:213-217.
117. Goadsby PJ, Duckworth JW. Low frequency stimulation of the locus coeruleus reduces regional cerebral blood flow in the spinalized cat. Brain Res. 1989;476:71-77.
118. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache. 1991;31:365-371.
119. Knight YE, Goadsby PJ. The periaqueductal gray matter modulates trigeminovascular input: a role in migraine? Neuroscience. 2001;106:793-800.
120. Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci. 2002;22:1-6.
121. Knight YE, Bartsch T, Goadsby PJ. Trigeminal antinociception induced by bicuculline in the periaqueductal grey (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. Neurosci Lett. 2003;336:113-116.
122. 1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann Neurol. 2004;56:371-381.
123. Potrebic S, Ahan AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin ID receptors: implications for the selective antimigraine action of triptans. J Neurosci. 2003;23:10988-10997.
124. 1F receptor expression in rat trigeminal ganglion (TRG) and dorsal root ganglia (DRG) neurons. Cephalalgia. 2002;22:595-596.
125. Drummond PD, Lance JW. Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol. 1983;13:32-37.
126. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerine) triggers genuine migraine attacks. Ear J Neurol. 1994;1:73-80.
127. Matharu MS, Goadsby PJ. Persistence of attacks of cluster headache after trigeminal nerve root section. Brain. 2002;175:976-984.
128. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24:1-160.